{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-130800","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.379294+00:00","generated_at":"2026-06-02T23:22:53.493374+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CG Oncology Phase 3 BOND-003: cretostimogene achieves 75.2% complete response in high-risk NMIBC","bullets":["75.2% complete response (79/105 patients; 95% CI: 65-83) at any time in BCG-unresponsive high-risk NMIBC.","29 patients maintained CR for ≥12 months; median duration of response not reached as of April 1, 2024.","92.4% cystectomy-free-survival; no CR patient had radical cystectomy or nodal/metastatic progression.","No Grade 3+ TRAEs; 1.8% serious TRAEs (Grade 2 cystitis, clot retention); no treatment discontinuations.","Topline data from fully enrolled Phase 3 BOND-003 expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-130800","json":"https://secwatch.observer/filing/0001193125-24-130800.json","markdown":"https://secwatch.observer/filing/0001193125-24-130800.md","text":"https://secwatch.observer/filing/0001193125-24-130800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524130800/0001193125-24-130800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524130800/d823423d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:22:53.493374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}